CDF之聲|武田制藥總裁兼CEO衛博科:中國將成為全球醫藥創新的重要源頭

CDF之聲|武田制藥總裁兼CEO衛博科:中國將成為全球醫藥創新的重要源頭
2022年03月07日 18:46 市場資訊

股市瞬息萬變,投資難以決策?來#A股參謀部#超話聊一聊,[點擊進入]

  來源:中國發展高層論壇

  過去的2021年,世紀疫情與國際變局持續交織,我國“兩個一百年”奮斗目標歷史交匯,中國與世界在激蕩中復蘇,企業和個人在磨礪中前行。

  這一年,在中國,許多行業與企業迎接著全新的發展機遇和行業趨勢;這一年,為中國,世界500強與行業領先企業的商業領袖們變中求新、變中求進,深耕中國,攜手共進,共創未來。

  今年的“CDF之聲”欄目邀請參會代表分享過去一年來自己與所領導的企業、所在行業的經歷以及他們的感悟。

  今天做客“CDF之聲”的武田制藥總裁兼CEO衛博科(Christophe Weber)。

  衛博科指出,席卷全球的新冠肺炎疫情更加凸顯出,擁有一個強有力的醫療保障體系,對于國家的經濟健康和人民福祉至關重要。他認為中國就是一個很好的例證。

  中國已經成為武田全球戰略中更為重要的板塊。他相信,隨著中國大力激勵創新,邁向更高質量的發展,中國將成為全球醫藥創新的重要源頭之一。

  展望后疫情時代,衛博科認為有三個重要的優先事項:

  第一,保障醫療衛生投入和研發至關重要。

  第二,我們必須共同努力,攜手應對全球變暖,保護地球。

  第三,新冠肺炎疫情讓我們認識到國際合作的重要性和價值,國際間的合作對于建立創新生態系統也同樣重要。

  以下為中英文原文:

  大家好!我謹代表武田制藥,感謝中國發展高層論壇邀請我們參與此次重要的對話。

  席卷全球的新冠肺炎疫情更加凸顯出,擁有一個強有力的醫療保障體系,對于國家的經濟健康和人民福祉至關重要。中國就是一個很好的例證。

  事實上,中國一直在持續加大資金投入、持續提升創新藥物可及性等舉措,為強化醫療體系建設做出不懈努力。這些舉措讓武田倍感振奮,并希望以此為契機,為中國患者帶來更多突破性的療法。

  中國的醫療衛生事業已經取得了卓有成效的進展。我想特別強調幾個方面:

  首先,中國的醫療衛生支出在GDP中所占的比重,已經從2019年的6.6%上升至2020年的7.1%,這一顯著增長將會極大惠及患者。

  其次,最新公布的國家醫保目錄納入了更多創新療法,以解決亟待滿足的中國患者所需,其中也包括武田制藥旗下2款罕見病藥物阿加糖酶α注射用濃溶液和醋酸艾替班特注射液。

  第三,在博鰲和大灣區開展的“先行先試”舉措,有助于進一步踐行中國政府“將人民群眾的健康放在第一位”的承諾。

  我們相信,中國將繼續致力于為民眾提供最好的藥物。鑒于此,中國已經成為武田全球戰略中更為重要的板塊。

  為了實現我們在中國的愿景,近期武田全球進行了戰略性的組織架構調整,這將有助于我們加速實現為中國患者帶來真正具有突破性的治療方案的承諾。同時,我們也相信,大力激勵創新,邁向更高質量的發展,將使中國在未來成為全球醫藥創新的重要源頭之一。

  由此,我也欣喜地和大家分享,我們正按計劃推動“到2025年在中國上市超過15款新產品”的目標,并且有望提前在2024年實現。

  展望后疫情時代,我認為有三個重要的優先事項:

  第一,保障醫療衛生投入和研發至關重要。過去十年間,人類預期壽命延長、生活方式改變,針對復雜疾病出現了更為先進的治療方案,這些都推動了醫療衛生領域的投資增長,并且其增速超過GDP和居民收入增速。近期的研發創新,推動了創新藥物在許多領域取得了顯著進展,但如果沒有政府的支持,缺乏持續投入的醫療資金、藥品定價背離了臨床價值,這些有可能會阻礙創新的發展。

  我們認為,以獲得突破性創新療法為導向的研發,其根本在于激勵創新。而中國正通過政策引導、優化營商環境、擴大開放等舉措營造更加優化的創新環境,尤其是在我們所處的醫藥行業。因此,我們也要共同努力,保護創新,在讓患者獲得更好的治療的同時,提升醫療體系效率和提供以價值為基礎的醫療服務。

  第二,我們必須共同努力,攜手應對全球變暖,保護地球。全球變暖有可能讓登革熱或寨卡這樣的疾病在更大的范圍內肆虐,我們要提前應對,不能等到真正發生時再予以關注。加強合作、加快臨床開發并增加對全球傳染病領域的投入,從而保護我們共同的生活環境免受疾病的肆虐和侵害。包括中國在內,每個人、每個國家都可以發揮作用。

  最后,新冠肺炎疫情讓我們認識到國際合作的重要性和價值。國際間合作對于建立創新生態系統將會一如既往的重要,讓我們為未來可能要面對的流行性疾病做好準備,而醫藥行業在其中發揮著重要作用。

  請允許我在此分享幾個例子:建立一個全球范圍、隨時備用的醫療產品儲備,如防護用品、醫療設備、檢測裝備、疫苗和治療藥物等;建立一個透明的全球預警系統,以便盡早發現疫情;以及投入研發資金,以更好地了解和預防人畜共患病,以及研發檢測裝備、疫苗和治療藥物來應對可能出現的病原體和疾病。

  過去二十年間,中國發展高層論壇在加深國際社會對中國的了解以及促進合作方面發揮了重要作用。如今,中國的醫藥市場持續增長,醫療衛生現代化進程取得重要進展,今年中國發展高層論壇的舉辦可謂恰逢其時。

  我期待學習中國在經濟社會發展、創新生態構建等領域的寶貴經驗。我也很高興能與大家分享武田制藥在全球、特別是在中國的發展規劃,包括持續的創新研發、數據和數字化,提高藥物可及性以及可持續發展等。

  再次感謝!期待在中國發展高層論壇期間與大家進一步交流!

  Hello, everyone! On behalf of Takeda, I would like to thank the China Development Forum for inviting us to be part of this important dialogue. 

  The global COVID-19 pandemic has demonstrated that a strong healthcare system is essential to a country’s economic health and wellbeing. China is no exception.

  In fact, China has been making a significant effort to elevate its healthcare system through increased funding and greater patient access to innovation. And that’s why we are excited about the opportunity for Takeda to bring more life-transforming treatments to people in China.

  In this journey for China’s healthcare modernization, there has been impactful progress. I would like to highlight a few areas in particular:

  First, China’s healthcare spend has increased from 6.6% of GDP in 2019 to 7.1% in 2020 – significant growth that will benefit patients.

  Second, the recent NRDL update included more innovative therapies to address high unmet needs in China, including 2 rare disease therapies from Takeda – Replagel and Firazyr.

  Finally, early access programs in Bo’Ao and the Greater Bay Area further reinforce China’s commitment to patient focused policies.

  We believe that China will continue to build on its commitment to bringing the best medicine to its citizens and as such, China has become an even more important part of Takeda’s global strategy.

  To support our vision for China, we recently evolved our global organization which we believe will help us accelerate our commitment to bringing truly life-transforming treatments to patients in China.  We also believe that China, if innovation is sufficiently rewarded, will become an important source of worldwide innovation in medicine in the future.

  On that note, I am happy to announce that we are on track to launch more than 15 innovative drugs in China by 2024.

  As we look ahead to our post-pandemic future, I see three important priorities:

  First, it will be critical to protect healthcare financing and research. In the last decade, increasing life expectancy, lifestyle changes and the availability of more advanced solutions for complex diseases have driven investment in health care to rise faster than GDP and incomes. While recent innovation has led to dramatic advances in many areas of medicine, without support from governments, instability in healthcare financing and drug prices could impede this progress. 

  We believe that rewarding innovation is fundamental to spurring research that leads to new, life-transforming treatments, and China has become increasingly favorable toward this, particularly in our industry. This is why we should work together to protect innovation while enabling better patient outcomes, including efforts to improve health care system efficiencies and value-based healthcare. 

  Secondly, we must work together to make a concerted effort to address global warming and protect the planet. The reality of an increasingly warmer world means that we can’t afford to wait until a disease such as dengue or Zika become more widespread before we take notice. Greater collaboration, accelerated clinical development and increased investment in global infectious diseases will be required to protect our shared environment from diseases that will ravage the developing world and threaten new geographies. Everyone has a role to play in affecting change here, including China.

  Finally, the COVID-19 pandemic has taught us the importance and value of international collaboration. This will continue to be critical in building an innovation ecosystem that can help prepare us for future pandemics and industry plays an important role in this. 

  Let me share a few examples which include: Establishing a worldwide inventory and ready-to-use stock of protective equipment, medical devices, testing kits, vaccines and treatments; A transparent global detection system must be created to detect outbreaks early on; and funding research to better understand and prevent zoonotic diseases as well as the diagnostic kits, vaccines and treatments against possible emerging pathogens and diseases.

  Over the past 20 years, the CDF has played a significant role in deepening the international community‘s understanding of China and opportunities for collaboration.Now with a growing pharmaceutical market and important progress being made to modernize healthcare in China, this year’s CDF event is particularly timely.

  I look forward to learning about China‘s valuable experience in economic and social development, innovation ecology and other fields. I’m also excited to share Takeda’s plans for continued innovation in research and development, data and digital, improving access to medicines and sustainable development both in our global efforts and in China specifically. 

  Thank you again and I will speak with you more during this week’s discussions at CDF!

  新浪聲明:所有會議實錄均為現場速記整理,未經演講者審閱,新浪網登載此文出于傳遞更多信息之目的,并不意味著贊同其觀點或證實其描述。

海量資訊、精準解讀,盡在新浪財經APP

責任編輯:張亞楠

人氣榜
跟牛人買牛股 入群討論
今日熱度
問股榜
立即問股
今日診股
產品入口: 新浪財經APP-股票-免費問股
產品入口: 新浪財經APP-股票-免費問股
產品入口: 新浪財經APP-股票-免費問股

APP專享直播

1/10

熱門推薦

收起
新浪財經公眾號
新浪財經公眾號

24小時滾動播報最新的財經資訊和視頻,更多粉絲福利掃描二維碼關注(sinafinance)

7X24小時

  • 03-11 均普智能 688306 --
  • 03-11 兆訊傳媒 301102 --
  • 03-10 哈焊華通 301137 15.37
  • 03-10 華融化學 301256 8.05
  • 03-10 何氏眼科 301103 42.5
  • 產品入口: 新浪財經APP-股票-免費問股
    新浪首頁 語音播報 相關新聞 返回頂部